Mira Pharmaceuticals (MIRA) Receivables (2023 - 2024)
Mira Pharmaceuticals' (MIRA) quarterly Receivables came in at $40439.0 in Q4 2024, up 139.82% year-on-year from $16862.0 in Q1 2024, and up 139.82% quarter-over-quarter from $16862.0 in Q4 2023.
Mira Pharmaceuticals (MIRA) Receivables (2023 - 2024) Analysis & Trends
Mira Pharmaceuticals has disclosed Receivables across 2 years of filings, most recently posting $40439.0 for Q4 2024.
- Receivables for Q4 2024 came in at $40439.0, up 139.82% year-over-year; the trailing twelve-month figure through Dec 2024 was $40439.0 (up 139.82% YoY), and the FY2024 annual result was $40439.0, up 139.82% from the prior year.
- Receivables came in at $40439.0 for Q4 2024 at Mira Pharmaceuticals, up from $16862.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $40439.0 in Q4 2024 to a low of $16862.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 10.46 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 21.18 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 17.72 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 12.48 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 9.52 Bn |
| 10 | Mira Pharmaceuticals | 22.73 Mn | 11.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 40,439.00 |
| Dec 31, 2023 | 16,862.00 |